(Note: Relief Therapeutics Holding SA withdrew its IPO plans in an SEC filing on Feb. 7, 2023. Relief Therapeutics filed its F-1 on Aug. 23, 2022; it not updated its prospectus since mid-November.)

(Background: Relief Therapeutics Holding SA filed an F-1/A dated Nov. 15, 2022, naming H.C. Wainwright & Co. as the underwriter for its IPO in the U.S. – a unit offering of American Depositary Shares (ADS) representing ordinary shares and warrants to buy ADS. Each unit represents one ADS and one warrant to buy one ADS. Each ADS represents 200 ordinary shares. Tne F-1/A did not disclose terms. The company’s ordinary shares trade on the SIX Swiss Exchange, where the last reported sale price for one ordinary share on Nov. 7, 2022, was 0.0315 CHF per common share, equivalent to a price of $6.36 per ADS as calculated by the official exchange rate on such date., according to the prospctus. Background: Relief Therapeutics Holding filed its F-1 on Aug. 23, 2022. It did not name an underwriter. The company calls this an IPO, but the prospectus reads like a NASDAQ uplisting from the SIX Swiss Exchange and the OTC market. Relief Therapeutics says its IPO will consist of American Depositary Shares (ADS). The company’s ordinary shares trade on the SIX Swiss Exchange under the symbol “RLF”. Its ordinary shares also currently trade on the over-the-counter market under the symbol “RLFTF” and its ADSs currently trade on the over-the-counter market under the symbol “RLFTY”. On Aug. 22, 2022, the last reported sale price of Relief Therapeutics’ ordinary shares on the SIX Swiss Exchange was 0.033 CHF per common share, equivalent to a price of $4.50 per ADS as calculated by the official exchange rate on such date.)

We are a Swiss commercial-stage biopharmaceutical company identifying, developing and commercializing novel patent-protected products in selected specialty, rare and ultra-rare disease areas on a global basis.

We currently focus on three therapeutic areas where we can best leverage our internal know-how and assets: Rare Metabolic Disorders, Rare Skin Diseases and Rare Respiratory Diseases. We are developing a direct commercial footprint in the United States (U.S.) and in Europe (EU), coupled with a strong network of commercial partners in the other major territories.

We leverage our internal R&D laboratories and track record in drug delivery systems and technologies to identify and take to market reformulated and/or repurposed drugs with a history of proven human safety and efficacy using a lean and capital-efficient organization where all key strategic functions are internalized, combined with an optimized network of outsourced service providers for various development activities.

Our products are intended for patients and care givers dealing with specialty, rare and ultra-rare debilitating diseases, by offering them novel treatment options engineered with patented drug delivery systems or repurposed and optimized drugs, to help them live their best possible lives and achieve their full potential.

Our diversified portfolio comprises a rare disease product that is commercialized in the EU and that we plan to launch in the U.S. in the last quarter of 2022, as well as a pipeline of products at various stages of development that are focused on rare and specialty diseases in selected therapeutic areas.